Literature DB >> 29056156

Dynorphin/Kappa Opioid Receptor Signaling in Preclinical Models of Alcohol, Drug, and Food Addiction.

Anushree Karkhanis1, Katherine M Holleran1, Sara R Jones2.   

Abstract

The dynorphin/kappa opioid receptor (KOR) system is implicated in the "dark side" of addiction, in which stress exacerbates maladaptive responses to drug and alcohol exposure. For example, acute stress and acute ethanol exposure result in an elevation in dynorphin, the KOR endogenous ligand. Activation of KORs results in modulation of several neurotransmitters; however, this chapter will focus on its regulatory effects on dopamine in mesolimbic areas. Specifically, KOR activation has an inhibitory effect on dopamine release, thereby influencing reward processing. Repeated stimulation of KORs, for example, via chronic drug and/or stress exposure, results in increased function of the dynorphin/KOR system. This augmentation in KOR function shifts the homeostatic balance in favor of an overall reduction in dopamine signaling via either by reducing dopamine release or by increasing dopamine transporter function. This chapter examines the effects of chronic ethanol exposure on KOR function and the downstream effects on dopamine transmission. Additionally, the impact of chronic cocaine exposure and its effects on KOR function will be explored. Further, KORs may also be involved in driving excessive consumption of food, contributing to the risk of developing obesity. While some studies have shown that KOR agonists reduce drug intake, other studies have shown that antagonists reduce addiction-like behaviors, demonstrating therapeutic potential. For example, KOR inhibition reduces ethanol intake in dependent animals, motivation to self-administer cocaine in chronic stress-exposed animals, and food consumption in obese animals. This chapter will delve into the mechanisms by which modulation of the dynorphin/KOR system may be therapeutic.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Addiction; Cocaine; Dopamine; Dynorphin; Ethanol; Kappa opioid receptor; Nucleus accumbens; Obesity; Stress

Mesh:

Substances:

Year:  2017        PMID: 29056156     DOI: 10.1016/bs.irn.2017.08.001

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  27 in total

1.  Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.

Authors:  Shawn M Flynn; Phillip M Epperly; April T Davenport; Gerta Cami-Kobeci; Stephen M Husbands; Mei-Chuan Ko; Paul W Czoty
Journal:  Neuropsychopharmacology       Date:  2019-04-10       Impact factor: 7.853

2.  Abuse Liability, Anti-Nociceptive, and Discriminative Stimulus Properties of IBNtxA.

Authors:  Ariful Islam; Mohammad Atiqur Rahman; Megan B Brenner; Allamar Moore; Alyssa Kellmyer; Harley M Buechler; Frank DiGiorgio; Vincent R Verchio; Laura McCracken; Mousumi Sumi; Robert Hartley; Joseph R Lizza; Gustavo Moura-Letts; Bradford D Fischer; Thomas M Keck
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-27

3.  Kappa opioid receptors in the bed nucleus of the stria terminalis regulate binge-like alcohol consumption in male and female mice.

Authors:  Harold L Haun; William C Griffin; Marcelo F Lopez; Howard C Becker
Journal:  Neuropharmacology       Date:  2020-02-02       Impact factor: 5.250

Review 4.  Involvement of Activated Brain Stress Responsive Systems in Excessive and "Relapse" Alcohol Drinking in Rodent Models: Implications for Therapeutics.

Authors:  Yan Zhou; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2018-04-18       Impact factor: 4.030

5.  Chemogenetic Manipulation of Dopamine Neurons Dictates Cocaine Potency at Distal Dopamine Transporters.

Authors:  Zachary D Brodnik; Wei Xu; Aashita Batra; Stacia I Lewandowski; Christina M Ruiz; Ole V Mortensen; Sandhya Kortagere; Stephen V Mahler; Rodrigo A España
Journal:  J Neurosci       Date:  2020-10-12       Impact factor: 6.167

Review 6.  Dopaminergic cellular and circuit contributions to kappa opioid receptor mediated aversion.

Authors:  Elyssa B Margolis; Anushree N Karkhanis
Journal:  Neurochem Int       Date:  2019-07-10       Impact factor: 3.921

7.  Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.

Authors:  Mei-Chuan Ko; Stephen M Husbands
Journal:  Handb Exp Pharmacol       Date:  2020-12-04

Review 8.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

Authors:  Chloe J Jordan; Jianjing Cao; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-19       Impact factor: 5.250

Review 9.  From Pleasure to Pain, and Back Again: The Intricate Relationship Between Alcohol and Nociception.

Authors:  Meridith T Robins; Mary M Heinricher; Andrey E Ryabinin
Journal:  Alcohol Alcohol       Date:  2019-12-01       Impact factor: 2.826

10.  Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior.

Authors:  Joshua D Gross; Shane W Kaski; Karl T Schmidt; Elizabeth S Cogan; Kristen M Boyt; Kim Wix; Adam B Schroer; Zoe A McElligott; David P Siderovski; Vincent Setola
Journal:  Neuropsychopharmacology       Date:  2019-05-29       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.